Trenbolone Hexahydrobenzylcarbonate represents the dominant large ester based Trenbolone compound on the market. It was first released by the France based Negma Laboratories in the late 1960’s under the trade name Parabolan. This represents the first and only Trenbolone hormone to ever exist in human grade form. Parabolan was prescribed for many years in cases of malnutrition, which will make a lot of sense as we dive into the compound. It was also prescribed to treat osteoporosis in some cases, as well as in the treatment of cachexia.
Testosterone Injections, like many anabolic steroids, was classified as a controlled substance in 1991. Testosterone is administered parenterally in normal and delayed-release (depot) forms. In September 1995, the FDA approved testosterone transdermal patches (Androderm), and many transdermal forms and brands are now available including implants, gels, and topical solutions. A testosterone buccal system, Striant, was FDA-approved in July 2003; Striant is a mucoadhesive product that adheres to the buccal mucosa and provides a controlled and sustained release of testosterone. In May 2014, the FDA approved an intranasal gel formulation of testosterone (Natesto). A transdermal patch (Intrinsa) for hormone replacement in women is under investigation; the daily dosages used in women are much lower than for products used in males. The FDA refused approval for Intrinsa in 2004 stating that more data regarding safety, especially in relation to cardiovascular and breast health, where required.